Sign in

CIK 0001664710

  • Non-accelerated filer
  • Smaller reporting company

Keros Therapeutics, Inc.

Sign in to watch
Ticker
KROS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
811173868
Phone
+1 617-314-6297
Business address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
  1. 4 Grant or award CHIEF EXECUTIVE OFFICER acquired 90,500 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 3 Insider Initial Statement of Ownership
  4. 4 Option exercise 10% owner acquired 1,700 shares (option exercise)
  5. 4 Derivatives Options or other derivatives
  6. 4/A Insider Changes in Ownership
  7. 4/A Insider Changes in Ownership
  8. 4 Grant or award Director acquired 5,250 shares (grant or award)
  9. 4 Grant or award Director acquired 5,250 shares (grant or award)
  10. 4 Grant or award Director acquired 5,250 shares (grant or award)
  11. 4 Grant or award Director acquired 5,250 shares (grant or award)
  12. 4 Grant or award Director acquired 5,250 shares (grant or award)
  13. 4 Grant or award Director acquired 5,250 shares (grant or award)
  14. 4 Grant or award Director acquired 5,250 shares (grant or award)
  15. 4 Grant or award Director acquired 5,250 shares (grant or award)
  16. 4 Open-market buy 10% owner bought 934,258 shares at an average $10.13 ($9,464,512)
  17. 3 Insider Initial Statement of Ownership
  18. 4 Option exercise CHIEF EXECUTIVE OFFICER acquired 49,367 shares (option exercise)
  19. 4 Grant or award Chief Medical Officer acquired 44,000 shares (grant or award)
  20. 4 Grant or award CHIEF FINANCIAL OFFICER acquired 44,000 shares (grant or award)

Page 3 of 11 · 206 filings